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Abstract 
Background and objective: Patient-reported outcome measures can provide clinicians with valuable information 
to improve doctor-patient communication and inform clinical decision-making. The aim of this study was to evaluate 
the physician-perceived utility of the QLQ-GINET21 in routine clinical practice in patients with gastrointestinal neu-
roendocrine tumours (GI-NETs). Secondary aims were to explore the patient, clinician, and/or centre-related variables 
potentially associated with perceived clinical utility.
Methods: Non-interventional, cross-sectional, multicentre study conducted at 34 hospitals in Spain and Portugal 
(NCT02853422). Patients diagnosed with GI-NETs completed two health-related quality of life (HRQoL) questionnaires 
(QLQ-C30, QLQ-GINET21) during a single routine visit. Physicians completed a 14-item ad hoc survey to rate the clini-
cal utility of QLQ-GINET21 on three dimensions: 1)therapeutic and clinical decision-making, 2)doctor-patient commu-
nication, 3)questionnaire characteristics.
Results: A total of 199 patients at 34 centres were enrolled by 36 participating clinicians. The highest rated dimen-
sion on the QLQ-GINET21 was questionnaire characteristics (86.9% of responses indicating “high utility”), followed by 
doctor-patient communication (74.4%), and therapeutic and clinical decision-making (65.8%). One physician-related vari-
able (GI-NET patient volume > 30 patients/year) was associated with high clinical utility and two variables (older age/
less experience treating GI-NETs) with low clinical utility.
Conclusions: Clinician-perceived clinical utility of QLQ-GINET21 is high. Clinicians valued the instruments’ capacity 
to provide a better understanding of patient perspectives and to identify the factors that had the largest influence on 
patient HRQoL.
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Introduction
Neuroendocrine tumours (NETs) are a heterogeneous 
group of relatively rare neoplasms primarily affecting 
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the lungs, pancreas, and gastrointestinal tract [1]. In 
most cases, gastrointestinal (GI)-NETs are slow-growing 
tumours that do not produce clear symptoms until they 
become metastatic [2–4]. Patients may present a wide 
range of symptoms, including fatigue, flushing, diar-
rhoea, dyspnoea, and mood swings, among others, all of 
which can severely impact health-related quality of life 
(HRQoL) [5–8]. The main aims of treatment are to con-
trol tumour growth, prolong survival [9], and provide 
symptom relief [7].
In recent years, there has been a growing interest in 
using patient-reported outcome measures (PROM) to 
assess patient perspectives to improve care [10, 11]. The 
use of these instruments to individually manage patients 
has been shown to improve doctor-patient communica-
tion [12, 13] as well as symptom control and HRQoL [12, 
14]. The most widely-used PROM for assessing HRQoL 
in cancer patients is the QLQ-C30, developed by the 
European Organisation for Research and Treatment of 
Cancer (EORTC). The condition-specific questionnaire, 
the EORTC QLQ-GINET21, was developed as an add-on 
module to the QLQ-C30 to better assess the symptoms 
and issues most relevant to patients with neuroendo-
crine tumours [15]. Given the relatively recent devel-
opment and validation of this instrument (2013), the 
number of published studies that have used this tool to 
assess HRQoL in patients with GI-NETs remains limited 
[7]. Moreover, the perceived clinical value of the QLQ-
GINET21 in routine practice has not been assessed to 
date.
In this context, the main aim of the present study was 
to evaluate the physician-perceived utility of the QLQ-
GINET21 for clinical and therapeutic decision-making in 
routine clinical practice. A secondary aim was to explore 
patient-, physician-, and/or centre-related variables 
potentially associated with the physician-perceived clini-
cal utility of this instrument.
Material and methods
Study design
This was an international, observational, non-interven-
tional, cross-sectional, multicentre study conducted 
in the context of routine clinical practice. In the course 
of a routine visit, participating patients completed two 
HRQoL instruments, the QLQ-C30 and QLQ-GINET21, 
and the participating physicians completed an ad hoc 
survey designed to gauge their opinion regarding the 
clinical utility of the QLQ-GINET21.
A total of 36 oncologists and endocrinologists from 
34 outpatient clinics in Spain and Portugal participated 
in the study (NCT02853422). The participating clinics 
were selected to obtain a representative sample of clini-
cal practice with a wide geographic spread. Reference 
centres for the treatment of NET in Spain and Portugal 
were pre-selected and invited to participate (100% agreed 
to do so). Given that these questionnaires are routinely 
used in clinical practice and in clinical studies, no specific 
training in the administration of these instruments was 
provided.
This study was approved by the Clinical Research Eth-
ics Committee of the Hospital Clínic (Barcelona, Spain). 
All patients provided written informed consent.
Patients
Inclusion criteria were: age > 18  years; diagnosis of GI-
NET during the past 12 months; ability to complete the 
study questionnaires and report self-perceived health sta-
tus. Exclusion criteria were: concomitant participation in 




The participating physicians completed a 14-item ad hoc 
survey (Table 1) individually for each patient immediately 
after the study visit. This instrument was designed spe-
cifically to assess the physician-perceived utility of the 
QLQ-GINET21 in routine clinical practice, both overall 
and on three specific dimensions, as follows: (1) thera-
peutic and clinical decision-making (7 items); (2) doctor-
patient communication (3 items); and (3) questionnaire 
characteristics (4 items). Each item had five response 
options, ranging from strongly disagree (0 point) to 
strongly agree (4 points), with higher scores indicating 
greater perceived utility. The maximum total score for 
each dimension varied according to the number of items, 
as shown in Table  2. Based on the total score on each 
dimension, the utility was classified as low, moderate, or 
high (Table 2). This ad hoc survey was not validated as it 
was specifically designed for the present study.
QLQ‑C30 and QLQ‑GINET21
All patients completed, as appropriate, the Spanish or 
Portuguese versions of these instruments, which were 
translated according to EORTC translation guidelines 
[16]. Both scales have been described in detail elsewhere 
[11, 15]. Briefly, however, the QLQ-C30 is composed of 
both multi-item scales and single-item measures which 
include 5 functional scales (cognitive, emotional, physi-
cal, role, and social functioning), 3 symptom scales 
(fatigue, nausea/vomiting, and pain), a global health 
status/QoL scale, and 5 single items assessing addi-
tional symptoms (appetite loss, constipation, diarrhoea, 
dyspnoea, and sleep disturbance), and perceived finan-
cial impact. All scale scores are linearly converted to 
range from 0 to 100, with higher scores indicating better 
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HRQoL or better function on the relevant scale. By con-
trast, for individual symptoms and symptom scales, 
higher scores indicate a higher symptom burden.
The 21-item QLQ-GINET21 questionnaire is adminis-
tered as an add-on module to the QLQ-C30. This ques-
tionnaire includes 4 items to assess muscle and/or bone 
pain, body image, sexual function, and information. The 
other 17 items are divided into five scales, as follows: 
endocrine symptoms (3 items), gastrointestinal symp-
toms (5 items), treatment-related symptoms (3 items), 
social functioning (3 items), and disease-related concerns 
(3 items). Responses are transformed linearly on a scale 
of 0-100, with higher scores indicating greater symptom 
severity [15, 17].
The paper-based questionnaires were completed by 
patients during the study visit. After filling out the ques-
tionnaires, the patients returned it to the investigator 
so that he/she could review the answers and, if neces-
sary, discuss them with the patient. If the patient did not 
understand a question or how to answer it, the investi-
gator could re-read the question or make minor clari-
fications, but never interpret the response or answer 
questions for the patient. Once the visit with the patient 
had been completed, the investigator transferred the 
responses from the questionnaires to the corresponding 
section of the study electronic case report form (eCRF) 
and filed it (with the patient’s consent). The question-
naires were scored during the analysis.
Study variables
Patient-related sociodemographic variables were: age, 
sex, employment status, marital status, and educational 
level. Clinical variables obtained from medical records 
were as follows: date of GI-NET diagnosis; diagnostic 
Table 1 Clinical utility survey
Therapeutic and clinical decision-making
Item 1. The patient’s responses have helped me to better understand the overall impact of the disease from patient’s point of view
Item 2. The patient’s responses have helped me to better understand the specific aspects/symptoms of the disease that are most limiting or that most 
affect the patient’s life
Item 3. I have considered the patient’s responses to the questionnaire when selecting the most appropriate treatment
Item 4. I have considered the patient’s responses when making changes in the dose and/or treatment regimen
Item 5. I have considered the patient’s responses when establishing the number and/or frequency of follow-up visits
Item 6. The patient’s responses have helped me to detect other possible health problems and I have referred the patient to other specialists (for exam-
ple psychiatry)
Item 7. The patient’s responses have helped me to better assess the patient’s current condition
Doctor-patient communication
Item 8. The use of this questionnaire improves doctor-patient communication
Item 9. The patient’s responses have allowed me to explore aspects of the disease that I do not usually ask about it during the visit
Item 10. The patient’s responses have helped me to determine whether the patient has received the correct information about his/her disease
Characteristics of the questionnaire
Item 11. The instructions are brief and easy for the patient to understand
Item 12. The wording of the questions is easy for the patient to understand
Item 13. The response options are easy to understand and the questionnaire is easy for the patient to fill out
Item 14. The characteristics of the questionnaire enable its routine use in clinical practice
Table 2 Characteristics and scoring of the clinical utility survey
Dimension Score range Utility classification
Therapeutic and clinical decision-making (7 items) 0–28 Low: 0–9
Moderate:10–19
High: 20–28
Doctor-patient communication (3 items) 0–12 Low: 0–4
Moderate:5–8
High: 9–12
Questionnaire characteristics (4 items) 0–16 Low: 0–5
Moderate: 6–11
High: 12–16
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procedure; time since first therapeutic intervention; cur-
rent medical treatment for GI-NET; treatment modi-
fications (if any) during the visit and reason for change; 
performance status (European Cooperative Oncology 
Group, ECOG); symptoms; and concomitant diseases 
and treatments. The patient’s current health status was 
assessed by the treating physician and rated as good, nei-
ther good nor poor, or poor, according to his/her clinical 
judgement. In addition, the physician was asked to indi-
cate the patient’s current health status as stable, improv-
ing, or worsening in comparison to prior visits. This 
assessment was based on a general clinical evaluation 
combined with data, when available, from biochemical, 
immunohistochemical, and/or imaging studies.
Physician-related variables were age, sex, and years of 
experience in treating patients with NETs. Centre-related 
variables were: hospital location (rural, metropolitan, 
urban) and hospital size (number of beds).
Outcome measures
The primary outcome measures were the three dimen-
sion-specific clinical utility scores obtained on the ad 
hoc survey, categorized as high, moderate, or low clinical 
utility.
Secondary outcome measures
Univariate and multivariate multilevel statistical mod-
els were performed to explore the potential association 
between the clinical utility scores obtained on the ad hoc 
survey and patient-, physician-, and centre-related study 
variables.
Statistical analysis
Descriptive statistics (means, standard deviations [SD], 
medians, and range) were used for continuous variables. 
Interquartile ranges were used where appropriate. The 
number and percentage of patients per response category 
was used to describe the categorical variables with 95% 
confidence intervals (CI). Parametric or non-parametric 
tests were used, as appropriate, to compare means and 
proportions. Pearson’s correlation (for continuous vari-
ables) and ANOVA (for categorical variables) were used 
to evaluate clinical utility.
Univariate and multilevel regression models were 
applied to each of the three dimensions to determine 
whether the variables were significantly associated with 
the clinical utility of QLQ-GINET21. The multilevel 
models had two levels, one including the physician- and 
centre-related variables and the second incorporat-
ing patient-related variables. The first model was a null 
model that did not include any independent variables but 
rather random intercepts to show the total variance in 
clinical utility between the centres/physicians. All patient 
variables with a P value < 0.2 on the univariate regression 
analyses were added to the second model (fixed effects). 
Finally, the physician- and centre-related variables were 
added to model 2 to create the third and final model.
Cronbach’s α was calculated for each dimension of 
the ad hoc survey to determine internal consistency. 
Values > 0.70 were considered acceptable. Statistical sig-
nificance was set at p < 0.05. The SAS Statistical software 
program, v. 9.01 (SAS Institute; Cary, NC, USA) was used 
to perform all statistical calculations.
Results
Physician‑ and centre‑related characteristics
A total of 36 physicians from 34 institutions participated 
in the study. Sociodemographic data were available for 
35 of the 36 physicians (97.2%). The mean (SD) age was 
42.7 (7.7) years and 51.4% were female. The mean (SD) 
years of experience treating NETs was 12.7 (6.7). Nearly 
all (34/35; 97.1%) of the participating physicians worked 
in metropolitan/urban areas, most (60.0%) in large hos-
pitals (> 500 beds). Slightly less than half (48.6%) of the 
physicians treated > 20 NET patients annually.
Patient characteristics
Of the 209 patients initially recruited, 10 were excluded 
for failure to meet the inclusion criteria (serious illness 
[n = 3], failure to complete the QLQ-GINET21 [n = 4], 
and inclusion after study deadline [n = 3]). Thus, 199 
patients (Spain, n = 194; Portugal, n = 5) were included 
in the final analysis. Of these patients, 92.3% completed 
both study questionnaires. Table 3 describes the patients’ 
sociodemographic and clinical characteristics (n = 199).
Clinical utility of QLQ‑GINET21 questionnaire
Table 4 shows the mean (SD) scores with 95% CI for the 
three dimensions assessed on the ad hoc survey.
Figure 1 shows the percentage of all responses for each 
dimension categorised as high, moderate, or low utility. 
The highest-rated dimension was questionnaire char-
acteristics while the lowest was therapeutic and clinical 
decision-making.
Figure 2 shows the percentage of responses that rated 
that item as having high (3–4 points), moderate (2 
points), or low clinical utility (0–1 point). As that figure 
makes clear, the highest rated aspects were items 1, 2, 7, 
11, 12, and 13 (high utility on > 85% of responses) while 
the lowest rated were items 3, 4, 5 (high utility in < 70%). 
See Table 2 for a description of the individual items.
Page 5 of 11Benavent et al. Health Qual Life Outcomes           (2021) 19:38  
Significant associations identified on the univariate 
analyses
Therapeutic and clinical decision‑making
The physician- and centre-related variables associated 
with higher clinical utility scores (mean [SD]) were as 
follows: female sex, 23.3 (4.6) vs. male sex, 19.9 (6.3), 
P < 0.0001; rural location vs. metropolitan or urban loca-
tion: 26.4 (3.1) vs. 19.8 (5.8) vs. 23.4 (5.4), P < 0.0001; 
and GI-NET patient volume > 30 patients/year, 23.7 
(4.1) vs. 21–30 patients, 17.6 (7.3), P < 0.0001. Patient-
related variables associated with high clinical utility were 
good health status: 21.8 (6.0) vs. poor health, 14.3 (4.8); 
P = 0.004; and ECOG 1 performance status, 22.2 (5.0) vs. 
ECOG 2/3, 17.9 (4.7), P = 0.017.
Doctor‑patient communication
Physician- or centre-related variables associated with 
higher utility were: female sex, 10.4 (1.9) vs. male sex, 
9.2 (2.8), P = 0.001; rural location: 11.4 (0.6) vs. urban, 
10.3 (2.8) and metropolitan locations, 9.4 (2.3), P < 0.001; 
and hospital size > 200 beds [200–499 beds, 10.0 (2.4) 
and > 500 beds, 9.7 (2.6)] vs. 100–199 beds, 6.3 (2.5), 
P = 0.030.
Patient-related variables associated with higher util-
ity were no current pharmacological treatment, 10.3 
(1.9) vs. current treatment, 9.5 (2.7), P = 0.028; ECOG 1 
performance status, 10.1 (2.2) vs. ECOG 2/3, 7.8 (2.9), 
P = 0.002; and GI-NET patient volumes: > 30 patients/
year, 10.5 (1.5) vs. 21–30 patients, 8.3 (2.9), P = 0.002.
Questionnaire characteristics
Hospital capacity (> 200 beds) was associated with higher 
utility (mean [SD]): 200–499 beds, 14.1 (2.0) and > 500 
beds, 14.0 (2.2) vs. 100–199 beds, 11.5 (0.6), P = 0.043. 
ECOG 1 performance status was also associated with 
higher utility: 14.31 (2.1) vs. ECOG 2/3, 13.0 (2.7); 
P = 0.047.
Multilevel models: significant associations
All patient-related variables that were close to statistical 
significance (P < 0.2) on the univariate regression analy-
ses were entered, together with the significant physi-
cian- and centre-related characteristics, in the multilevel 
models. The results obtained in the final model (model 3) 
are shown in Table 5 and the key findings for each of the 
three dimensions are summarized below in Table 6.
Therapeutic and clinical decision‑making
Only one patient-related variable (male sex) was signifi-
cantly associated with higher utility. High patient vol-
umes (> 30 GI-NET patients/year) were associated with 
higher utility. By contrast, a metropolitan work location 
was associated with lower utility.
Table 3 Patient sociodemographic and  clinical 
characteristics
a All data, except where indicated otherwise, are based on the full sample 
(n = 199). In all cases, the percentages are calculated based on the available data
b Based on general clinical assessment and, when available, data from 
biochemical, immunohistochemical, and/or imaging studies
ECOG, European Cooperative Oncology Group; GI-NET, gastrointestinal 
neuroendocrine tumour; SD, standard deviation
Characteristic Patientsa
Age, years, mean (SD) 61.9 (13.1)
Sex , n (%)
Male 111 (55.8%)
Female 88 (44.2%)





Educational leve [(n = 179), n (%)] 
No formal education 18 (10.1%)
Primary education 68 (38.0%)
Secondary education 52 (29.1%)
University studies/postgraduate studies 41 (22.9%)
Time elapsed in years since diagnosis of GI-NET , mean (SD) 2.87 (3.6)
Time elapsed (years) since the 1 st intervention , mean (SD) 2.73 (3.6)
Time elapsed (months) between diagnosis and 1 st intervention , 
mean (SD)
1.7 (5.9)
Pharmacological treatment , n (%)
No current pharmacological treatment 67 (33.7%)
Somatostatin analogues 113 (56.8%)
Chemotherapy 21 (10.6%)
Interferon 2 (1.0%)
Targeted therapy 21 (10.6%)
Other 5 (2.5%)
Presence of symptoms , n (%)
No 104 (52.3%)
Yes 95 (47.7%)




ECOG scores, n (%)
ECOG 0 100 (50.3%)
ECOG 1 81 (40.7%)
ECOG 2 16 (8.0%)
ECOG 3 2 (1.0%)
Presence of concomitant illness, n (%) 75 (37.7%)
No
Yes 124 (62.3%)
Clinical assessment of patient’s health, n (%)
Good 169 (84.9%)
Neither good nor poor 9 (4.5%)
Poor 21 (10.6%)
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Doctor‑patient communication
Physician-perceived clinical utility of the QLQ-GINET21 
was significantly lower in patients with an “improv-
ing” health status vs. stable/worsening and for those 
with “poor” versus “good” health status. Two physician-
related variables (older age and less experience in treat-
ing patients with NETs) were significantly associated 
(P < 0.05) with lower clinical utility on this dimension.
Questionnaire characteristics
Two physician-related variables (older age and less expe-
rience in treating patients with NETs) were both signifi-
cantly associated (P < 0.05) with lower clinical utility on 
this dimension.
Internal consistency of the ad hoc survey
To determine the internal consistency of the scale, we 
calculated the Cronbach’s α for all three dimensions 
therapeutic and clinical decision-making, doctor-patient 
communication, and questionnaire characteristics), with 
values > 0.80 on all three dimensions (respectively, 0.807, 
0.898 and 0.908), thereby indicating good reliability.
Discussion
The main objective of the present study was to assess 
physician perspectives regarding the clinical value of 
administering the QLQ-GINET21 in routine clinical 
practice. Overall, our findings show that the clinicians 
surveyed considered this instrument to have a high 
clinical utility (Figs.  1, 2). The highest-rated dimension 
was questionnaire characteristics, followed by doctor-
patient communication, and finally therapeutic and 
clinical decision-making. The highest-rated items on the 
survey (Fig.  2, Table  1) were items 1, 2, 7, 11, 12, and 
13 (rated “high utility” in > 85% of cases) while the low-
est rated items were items 3, 4, 5 (< 70% of “high utility” 
ratings). On the multilevel model, one physician-related 
parameter (GI-NET patient volumes > 30/year) was asso-
ciated with high clinical utility for therapeutic and clini-
cal decision-making. Two physician-related variables 
(older age and less experience treating GI-NETs) were 
associated with low clinical utility on two dimensions 
(doctor-patient communication and questionnaire char-
acteristics). Overall, these findings confirm that physi-
cians find the QLQ-GINET21 to be useful to help inform 
clinical practice.
The results of this clinician survey show that these 
professionals highly valued the brevity, clarity, and ease 
of administration of the QLQ-GINET21, character-
istics that allow for rapid administration in the clinic, 
which allows them to provide patients with immedi-
ate feedback, thus improving doctor-patient commu-
nication. Our findings suggest that the main clinical 
utility of the instrument from the physicians’ perspec-
tive is that it provides a better global understanding of 
Table 4 Clinical utility of the QLQ-GINET21: results of the ad hoc survey
CI, confidence interval; SD, standard deviation
Dimension Mean score (SD); 95% CI Utility
Therapeutic and clinical decision-making (7 items) 21.4 (5.8); 20.6–22.2 High
Doctor-patient communication (3 items) 9.8 (2.5); 9.4–10.1 High
Questionnaire characteristics (4 items) 14.0 (2.1); 13.7–14.3 High
Fig. 1 QLQ-GINET21: clinical utility by dimension
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patient perspectives, particularly those factors that most 
impact HRQoL, including aspects that may otherwise be 
overlooked.
There is a large and growing body of literature[18–21] 
on the role and benefits of condition-specific PROMs, 
showing that the routine use of such instruments can 
improve communication between doctors and their 
patients and help with clinical decision-making. The 
findings of the present study confirm these benefits for 
the QLQ-GINET21. While some clinicians may be reluc-
tant to systematically administer PROMs due to concerns 
about the associated increase in workload and/or mis-
conceptions about the utility of such instruments [22], 
assessing patient perspectives has become increasingly 
relevant, particularly in patients with GI-NETs, who have 
a relatively long life expectancy and for whom quality of 
life is a key outcome measure [23].
Therapeutic and clinical decision‑making
The dimension that received the lowest clinical utility 
ratings (considered “high utility” in only 65.8% of cases) 
was therapeutic and clinical decision-making. However, 
if we group the “high” and “moderate” utility scores, this 
percentage rises to approximately 95%, indicating an 
overall moderate-to-high support for the clinical utility 
of the QLQ-GINET21 for clinical decision-making. The 
relatively lower perceived utility of this dimension (Fig. 1) 
versus the other dimensions is not surprising given that 
this dimension comprises the most complex aspects 
of patient care, and patient-reported data are only one 
piece of the complex clinical picture that the clinician 
must consider. Moreover, the capacity of this instrument 
to help improve clinical decision-making is limited by 
the fact that the minimal clinical important differences 
(MCID) for this instrument have yet to be defined[23].
As Fig. 2 shows, the items with the greatest perceived 
clinical utility in this dimension were the items that 
help to provide a better understanding of the patient’s 
Fig. 2 Clinical utility for each item on the ad hoc survey
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Table 5 Multilevel model outcomes for patient-related  variablesa





Therapeutic and clinical decision‑making Doctor‑patient communication Questionnaire characteristics
Sex






Female – Single – 0.61 (0.59) Retired – 0.10 (0.40)
Widowed – 0.11 (0.58) Unemployed 0.25 (0.43)
Separated/divorced – Employed – 
Time since NET diagnosis 0.74 (0.49) Course of 
patient’s clini-
cal status








Improving – Improving – 
Time since first therapeutic 
intervention





Neither good nor bad 1.72
(0.79)
Poor – 
Table 6 Multilevel model outcomes for physician- and centre-related variables
Entries show parameter estimates with standard errors in parentheses
*p < 0.05
Estimation method = ML; Satterthwaite degrees of freedom. NET, neuroendocrine tumours
Multilevel model
















Years of experience treating NETs 0.03 (0.23) 0.28 (0.11)* 0.28 (0.10)*
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perspective regarding the impact of the disease (item 1), 
the aspects that most impact QoL (item 2), and current 
disease status (item 7). The relatively high clinical utility 
of these items suggest that physicians are interested in 
obtaining a greater understanding of the patient’s per-
spective. By contrast, the items with the lowest perceived 
utility (all of which received a score of 3 or 4 in < 70% 
of cases) were items 3 (treatment selection), 4 (chang-
ing dose or treatment regimen), and 5 (establishing fre-
quency/number of follow-up visits).
Doctor‑patient communication
The three items on this dimension all received similar 
utility ratings (around 80%), indicating that, in general, 
the physicians considered the questionnaire to be of value 
in improving communication. Item 8 on this dimension 
assesses the value of the questionnaire to improve doc-
tor-patient communication in general. Item 9 refers to 
the value of the QLQ-GINET21 to explore overlooked 
aspects of the disease. Item 10 refers to the value of the 
questionnaire to help determine whether the patient has 
received enough information about the disease. Overall, 
the findings on this dimension suggest that the QLQ-
GINET21 may help to improve doctor-patient commu-
nication. a finding that is in line with previous reports 
regarding the QLQ-C30 and similar instruments [18–20].
Questionnaire characteristics
This dimension, which broadly assesses the design and 
ease of use of the QLQ-GINET21, was the most highly 
rated, indicating that the physicians in this survey believe 
that the questionnaire is sufficiently brief and easy to 
understand, clearly-worded, and easy to complete. More-
over, these results are supported by the high comple-
tion rate (92.3%) of the QLQ-GINET21 in our cohort, a 
finding that is consistent with the 90% completion rates 
reported by Yadegarfar et  al. in the validation study for 
this instrument [15]. Notably, the lowest-rated item 
(80.4%) in this dimension was item 14 “the characteris-
tics of the questionnaire enable its routine use in clinical 
practice”, indicating that some physicians believe there 
are impediments to using the questionnaire in routine 
practice. In this regard, the QLQ-GINET21 is generally 
administered together with the QLQ-C30, thus increas-
ing the time needed for completion. Indeed, a pilot 
study conducted by Van Leeuwaarde et  al.[24] to assess 
patient (rather than physician) perceptions of the QLQ-
GINET21 found that 13% of the respondents considered 
the questionnaire either too long or too tiring. This find-
ing, considered together with our results, suggests that 
the instrument could potentially benefit from further 
refinement, such as removing the least valued aspects (as 
rated by physicians and/or patients) to reduce the time 
needed to complete the QLQ-GINET21. For example, 
in our survey, 7.5% of respondents indicated that item 
10 (which asks whether patients have received enough 
information about the disease) had little clinical util-
ity. Despite the proven utility of HRQoL questionnaires, 
their use in clinical practice is sometimes limited due to 
time limitations [25], which may be particularly relevant 
in patients with GI-NETs in whom fatigue is a common 
symptom.
A secondary, exploratory aim of this study was to 
identify patient-, physician-, or centre-related variables 
that might be associated with perceived clinical util-
ity. On the multilevel model, high NET patient volume 
(> 30 patients/year) was associated with higher perceived 
utility on the therapeutic and clinical decision-making 
dimension, perhaps because physicians who treat more 
patients have greater experience in using and interpret-
ing the results of the QLQ-GINET21. Conceivably, as 
physicians become more familiar with the instrument, 
this could increase their ability to use it more effectively 
and interpret it more quickly. Two other physician-
related variables (older age and less experience) were 
associated with low clinical utility on two dimensions 
(doctor-patient communication and questionnaire char-
acteristics). The association between older physician 
age and lower clinical utility is consistent with previ-
ous reports [26, 27]. However, in our study, this finding 
appears to contradict our other finding that less experi-
ence in treating NETs was also associated with low clini-
cal utility. These contradictory findings are difficult to 
explain but may be related to the relatively small num-
ber of participating physicians (n = 36). The routine use 
of PROMs in clinical practice has increased substantially 
in the past two decades. Numerous studies have dem-
onstrated the value of these instruments to inform care 
[28] and to improve communication [12, 13], symptom 
control, and HRQoL [12, 14]. Such instruments are par-
ticularly valuable in chronic diseases with a high symp-
tom burden such as GI-NETs. However, the development 
and validation of these instruments is a complex, time-
consuming process that requiring an ongoing evalua-
tion process through field-use and studies such as ours. 
The QLQ-GINET21 is a relatively new instrument and 
it is imperative that we continue to refine it for the ben-
efit of both patients and clinicians alike. Studies such as 
ours and that by Van Leeuwaarde et al. [29] can provide 
valuable data that can be used to improve these question-
naires. For instance, those authors found that while most 
(83%) of the patients who completed the survey consid-
ered that the instrument provided a moderate (30%) or 
good (53%) indication of their HRQoL, nearly one in five 
(18%) patients considered it a “poor” representation of 
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their HRQoL. These findings, considered together with 
the results of our study, underscore the importance of 
assessing PROMs such as the QLQ-GINET21 from the 
perspective of both clinicians and patients.
Study strengths and limitations
This study has several limitations. First, the number of 
participating centres and clinicians was relatively small, 
making it difficult to draw statistically significant conclu-
sions, especially regarding to the physician- and centre-
related variables. In addition, this was a cross-sectional 
study with only a single HRQoL assessment per patient.
Another limitation is that the QLQ-GINET21 was 
designed for use at an aggregate level, rather than for 
individual patients. Since the MCID for this instrument 
have not been defined and validated[23], this could have 
impeded the clinician’s ability to accurately interpret the 
items, potentially leading the participants to overrate 
the true utility of certain items. By contrast, the main 
strength of this study is that it is the first to assess the 
perspective of physicians regarding the clinical utility of 
the QLQ-GINET21 in routine clinical practice.
Conclusions
The findings of this study show that the participat-
ing physicians consider the QLQ-GINET21 to have a 
high clinical utility. The most highly-rated aspect was 
the characteristics of the questionnaire design (brevity, 
comprehensibility, and ease of administration). For clini-
cal decision-making, the most highly-rated facets of the 
QLQ-GINET21 were its capacity to provide a general 
understanding of patient perspectives and, more specifi-
cally, the disease-related aspects with the greatest impact 
on patient HRQoL.
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